ライフサイエンスコーパス: islet transplantation

1 ts using CMRL 1066 medium (used for clinical islet transplantation).

2 undergoing total pancreatectomy (autologous islet transplantation).

3 tained normoglycemia for up to 60 days after islet transplantation.

4 tion of therapeutic interventions, including islet transplantation.

5 ft function still remains inconsistent after islet transplantation.

6 as a new approach to improve the outcomes of islet transplantation.

7 rix components present in pancreas, prior to islet transplantation.

8 rapies, as adjuncts for immunosuppression in islet transplantation.

9 for insulin independence after single-donor islet transplantation.

10 for patients with type 1 diabetes undergoing islet transplantation.

11 DSCs as a novel adjunctive immunotherapy for islet transplantation.

12 three patients immediately after intraportal islet transplantation.

13 ight, and fasting blood glucose levels after islet transplantation.

14 tolerance induction for clinical xenogeneic islet transplantation.

15 hat GABA might find applications in clinical islet transplantation.

16 (de novo expression or titer increase) after islet transplantation.

17 Rs may be a useful adjunct therapy for human islet transplantation.

18 t rejection is one of the main obstacles for islet transplantation.

19 ulin-dependent) diabetes mellitus, including islet transplantation.

20 justify early clinical trials of IDN6556 in islet transplantation.

21 rategy is likely to improve outcome in human islet transplantation.

22 n of a macrochamber specially engineered for islet transplantation.

23 their depletion can thus be advantageous for islet transplantation.

24 nd protein expression levels increased after islet transplantation.

25 fect of B-cell depletion in murine models of islet transplantation.

26 beneficial as an alternative to intrahepatic islet transplantation.

27 i-islet immune response in various models of islet transplantation.

28 ly aid in increasing the success of clinical islet transplantation.

29 in early islet graft loss after intraportal islet transplantation.

30 n vivo in allogenic and autoimmune models of islet transplantation.

31 ytotoxicity, but not splenic NK cells, after islet transplantation.

32 pendence in type 1 diabetic recipients after islet transplantation.

33 RL) has beneficial effects on beta cells for islet transplantation.

34 ation and beta-cell death by apoptosis after islet transplantation.

35 status affect the choice between pancreas or islet transplantation.

36 tation with islet grafts in a mouse model of islet transplantation.

37 ts instead of culturing for current clinical islet transplantation.

38 its potential use in the context of clinical islet transplantation.

39 ow use this purification method for clinical islet transplantation.

40 te (GFR) have been observed after successful islet transplantation.

41 might be an alternative site for pancreatic islet transplantation.

42 unction with low dose tacrolimus, in current islet transplantation.

43 ur way to clinical use of in vivo imaging of islet transplantation.

44 ing of LMW-DS for the prevention of IBMIR in islet transplantation.

45 the outcome of diabetic patients undergoing islet transplantation.

46 contribution by the European Consortium for Islet Transplantation.

47 lity, negatively affecting outcomes of human islet transplantation.

48 ch to successfully establishing subcutaneous islet transplantation.

49 ntly used immune suppression (IS) regimen in islet transplantation.

50 erred with severe hypoglycemia, suitable for islet transplantation.

51 its importance in clinical settings such as islet transplantation.

52 viable islet mass after clinical intraportal islet transplantation.

53 is currently incompatible with intrahepatic islet transplantation.

54 lear cell co-cultured exosomes for improving islet transplantation.

55 tuate disease and are rapidly reactivated by islet transplantation.

56 beta cell dysfunction in type 2 diabetes and islet transplantation.

57 unction, both of which hinder the success of islet transplantation.

58 The Clinical Islet Transplantation 07 (CIT07) protocol uses antithymo

59 Before islet transplantation, 10 patients (59%) were screened p

60 s revealed US $57,525 of additional cost for islet transplantation 5 years after transplantation.

61 1 diabetes receiving an intra-BM allogeneic islet transplantation: a feasibility study in patients w

62 ise for overcoming two major issues in human islet transplantation: (a) poor yield of islets from don

63 Clinical islet transplantation achieves insulin independence in s

64 Islet transplantation after successful kidney transplant

65 istry reports have suggested that results of islet transplantation alone in this indication may be ab

66 Transplants in the IAK and islet transplantation alone setting demonstrated similar

67 in our program where nine patients underwent islet transplantation alone treated with Edmonton immuno

68 Kidney function remained stable after islet transplantation alone.

69 centrations were monitored for 30 days after islet transplantation and animals were then subjected to

70 with type 1 diabetes who received pancreatic islet transplantation and anti-CD25 mAb as induction the

71 use of rapamycin as an immunosuppressant in islet transplantation and as a second-line agent in othe

72 This addresses a key challenge facing islet transplantation and importantly, the clinical appl

73 improving beta-cell survival following human islet transplantation and increasing beta-cells in patie

74 We investigated whether islet transplantation and insulin treatment can relieve

75 mulates specifically in the beta-cells after islet transplantation and is a promising tracer for noni

76 e results and could be performed both before islet transplantation and on preserved cell blocks at an

77 potential to improve graft survival in human islet transplantation and other cellular therapies on th

78 sulin production in both type 2 diabetes and islet transplantation and point to the potential for the

79 ed macaques underwent intraportal allogeneic islet transplantation and received basiliximab and sirol

80 at the adrenal may be an attractive site for islet transplantation and that GHRH analogs might allow

81 mycin could negatively impact the success of islet transplantation and the adaptation of beta-cells t

82 ediated attack is a substantial challenge in islet transplantation and this will extend to applicatio

83 nts who became insulin independent after one islet transplantation and those who did not.

84 Ig)-like transcript (ILT) 3-Fc in pancreatic islet transplantation and to determine its mechanism of

85 study aimed to evaluate long-term effects of islet transplantation and to outline possible influentia

86 ed insulin independence after a single-donor islet transplantation, and 149 did not.

87 ul tools for studying beta-cell development, islet transplantation, and beta-cell autoimmunity.

88 ost active region in the field of pancreatic islet transplantation, and many of the leading groups ar

89 moglycemia in diabetic mice after pancreatic islet transplantation, and results in reduced tumor volu

90 Whole pancreas and islet transplantation are currently used for the treatme

91 eversal of liver ischemia due to intraportal islet transplantation are detectable using T2-weighted M

92 Recent advances in human islet transplantation are hampered by significant graft

93 DSA or autoantibody increases after islet transplantation are important prognostic markers,

94 Both pancreas and islet transplantations are therapeutic options for compl

95 In this study, we used allogeneic islet transplantation as a model indication to assess th

96 aft survival limits the long-term success of islet transplantation as a potential curative therapy fo

97 ls significantly increased after intraportal islet transplantation as compared with the control.

98 The applicability of islet transplantation as treatment for type 1 diabetes i

99 from patients with autologous and allogeneic islet transplantation as well as total pancreatectomy al

100 Islets transplantation, as a treatment of type 1 diabete

101 Subjects undergoing islet transplantation at a single center (Edmonton, Cana

102 of graft survival in the stringent model of islet transplantation (BALB/c into NOD).

103 biomarker to detect graft damage in clinical islet transplantation because serum C-peptide and proins

104 As islet transplantation begins to show promise as a clinic

105 Thus, they may improve islet transplantation by delivering small RNAs for promo

106 roves islet graft survival after intraportal islet transplantation by mitigation of coagulation in IB

107 e results provide evidence that intrahepatic islet transplantation can restore glucose counterregulat

108 Islet transplantation can restore normoglycemia to patie

109 Islet transplantation can temporarily cure type 1 diabet

110 onal Institutes of Health-sponsored Clinical Islet Transplantation (CIT) Consortium jointly developed

111 Whilst islet transplantation combined with immune suppression h

112 Islet transplantation consisted of three sequential fres

113 The Clinical Islet Transplantation consortium 01 study was a phase II

114 Outcomes after islet transplantation continue to improve but etiology o

115 bjects with severe hypoglycemia suitable for islet transplantation, CSII decreased hypoglycemia frequ

116 Long-term insulin independence after islet transplantation depends on engraftment of a large

117 Subcutaneous tissue is a promising site for islet transplantation, due to its large area and accessi

118 is the current site of choice for pancreatic islet transplantation, even though it is far from being

119 ntly depleted B cells in all three models of islet transplantation examined.

120 Islet transplantation favoring ATZ induction is associat

121 enchymal stem cells for tissue regeneration, islet transplantation for diabetes treatment, and T cell

122 Pancreatic resection with autologous islet transplantation for severe chronic pancreatitis is

123 Pancreatic beta-cell replacement by islet transplantation for the treatment of type 1 diabet

124 ucted in 35 subjects submitted to pancreatic islet transplantation for treatment of unstable type 1 d

125 Problems associated with islet transplantation for Type 1 Diabetes (T1D) such as

126 cantly improving the therapeutic efficacy of islet transplantation for type 1 diabetes.

127 cells within islets results in diabetes, and islet transplantation from cadaveric donors can cure the

128 Thus, allogeneic islet transplantation had a positive systemic effect in

129 e of the recipient of an intra-BM allogeneic islet transplantation had a primary nonfunction, as show

130 Because islet transplantation has become a promising treatment o

131 Clinical islet transplantation has become an established treatmen

132 Islet transplantation has been reported to induce allose

133 his article, we address the question whether islet transplantation has indeed bridged the gap with wh

134 The impact of IA on islet transplantation has never been explored.

135 migration, their influence on the outcome of islet transplantation has not been characterized.

136 Since 2000, intrahepatic islet transplantation has proven efficacious in alleviat

137 Islet transplantation has proven to be a successful stra

138 Clinical islet transplantation has recently been a promising trea

139 Islet transplantation has recently emerged as an accepta

140 Pancreatic islet transplantation has shown great success in the tre

141 Pancreatic islet transplantation has the potential to cure type 1 d

142 omposite measure of beta cell function after islet transplantation, has limited sensitivity because o

143 Until recent years, outcomes of islet transplantation have been significantly inferior t

144 After islet transplantation, HbA1c was normalized, and time sp

145 After islet transplantation, IA-positive patients achieved ins

146 study was to determine whether intrahepatic islet transplantation improves endogenous glucose produc

147 iver and islet engraftment after intraportal islet transplantation in a clinical setting.

148 e report that the efficiency of subcutaneous islet transplantation in a Lewis rat model is significan

149 nvestigate tolerance induction protocols for islet transplantation in a setting of autoimmunity.

150 ent of glycemic control following pancreatic islet transplantation in animal models is discussed.

151 Following syngeneic renal sub-capsule islet transplantation in C57/B6 mice, pFUS (PNP: 2.9 MPa

152 We showed that islet transplantation in confined well-vascularized site

153 t feasibility and safety of BM as a site for islet transplantation in humans.

154 Islet transplantation in man is limited by multiple fact

155 nd monitors comprehensive data on allogeneic islet transplantation in North America, Europe, and Aust

156 the metabolic outcomes and graft survival of islet transplantation in our program where nine patients

157 Previous studies have shown that islet transplantation in the testis significantly prolon

158 nd prevents recurrence of autoimmunity after islet transplantation in ~50% of NOD mice.

159 In-depth analysis reveals that islet transplantation, in fact, has an edge on whole pan

160 have concentrated their efforts on improving islet transplantation, in particular by fabricating bioa

161 autoimmune setting, such as with pancreas or islet transplantation into a type 1 diabetic individual,

162 nhibited human beta-cell apoptosis following islet transplantation into NOD/scid mice.

163 glycemia, we developed a model of pancreatic islet transplantation into the liver.

164 Islet transplantation into the scaffold resulted in norm

165 -producing beta cells in type 1 diabetes and islet transplantation involves a variety of immune pathw

166 Although human islet transplantation is a cell-based therapy under clin

167 Islet transplantation is a feasible therapeutic alternat

168 Islet transplantation is a poorly investigated long-term

169 beta-Cell replacement by islet transplantation is a potential curative therapy fo

170 Islet transplantation is a potential treatment for type

171 Pancreatic islet transplantation is a promising clinical treatment

172 Pancreatic islet transplantation is a promising potential cure for

173 Islet transplantation is a promising therapeutic approac

174 Islet transplantation is a promising treatment for T1D,

175 Islet transplantation is a promising treatment for type

176 Islet transplantation is a promising treatment for type-

177 pancreatic beta-cells through deceased donor islet transplantation is a proven therapy for preventing

178 Pancreatic islet transplantation is a rapidly evolving field.

179 Islet transplantation is a recognized treatment option f

180 ulin delivery are inadequate, and allogeneic islet transplantation is a safe alternative for those pa

181 Islet transplantation is a successful beta-cell replacem

182 reatment of patients with type 1 diabetes by islet transplantation is affected by a multitude of fact

183 Islet transplantation is an alternative to pancreas tran

184 Islet transplantation is an effective method to obtain l

185 Islet transplantation is an effective therapy for life-t

186 Islet transplantation is an effective therapy in type 1

187 Autologous islet transplantation is an elegant and effective method

188 Islet transplantation is an emerging therapy for type 1

189 Islet transplantation is an established therapy for diab

190 Allogeneic islet transplantation is an important therapeutic approa

191 Islet transplantation is associated with long-term impro

192 However, a key challenge for islet transplantation is cellular rejection and the requ

193 rease of MMP-9 expression and activity after islet transplantation is directly related to enhanced le

194 Cost analysis revealed that islet transplantation is estimated to be cost neutral at

195 Clinical islet transplantation is generally conducted within 72 h

196 Long-term clinical outcome of islet transplantation is hampered by the rejection and r

197 Allogeneic islet transplantation is limited by adverse effects of c

198 Islet transplantation is limited by the need for chronic

199 e compounded by the induction of diabetes if islet transplantation is planned.

200 nsulin resistance, and their avoidance after islet transplantation is preferred from a metabolic stan

201 Islet transplantation is primarily performed alone in pa

202 A major challenge for human allogeneic islet transplantation is the development of effective me

203 A significant barrier to islet transplantation is the rapid loss of human islet f

204 For pancreatic islet transplantation, islet purification minimizes the

205 l state of type-1 diabetes as well as during islet transplantation.Islet transplantation is considere

206 h the liver is the primary site for clinical islet transplantation, it poses several restrictions, es

207 onal status and behavior are associated with islet transplantation (ITx) and to assess their possible

208 , synergistically enhance angiogenesis after islet transplantation leading to stable engraftment.

209 oidance of steroids; however, the outcome of islet transplantation may differ in kidney transplant re

210 with insulin independence after single-donor islet transplantation may help to select recipient-donor

211 Pancreatic islet transplantation may provide an effective therapy f

212 tched, nonlymphopenic, immunocompetent mouse islet transplantation model, alloTregs but not nTregs pr

213 ransplantation has already been proven in an islet transplantation model, skin graft survival could n

214 reventing allograft rejection using a murine islet transplantation model.

215 ned and may best be addressed using a unique islet-transplantation model.

216 Using allogeneic islet transplantation models as well as NOD mice with re

217 In intraportal islet transplantation models using mouse and human islet

218 Using adoptive transfer and islet transplantation models, we demonstrate that TLO fo

219 in vivo on INS-1 tumor (GLP-1R positive) and islet transplantation models.

220 slets at 4 degrees C improves the outcome of islet transplantation more efficiently than preservation

221 Clinical islet transplantation needs to be evaluated using the mo

222 Because of the lack of tissue available for islet transplantation, new sources of beta-cells have be

223 ce and 100% indefinite survival of syngeneic islet transplantation (NOD.SCID into NOD mice).

224 Islet transplantation normalized glycemia and increased

225 Pancreatic islet transplantation offers a promising biotherapy for

226 Human pancreatic islet transplantation offers diabetic patients tight glu

227 ry confirm the inarguably positive impact of islet transplantation on metabolic control in T1 diabete

228 tion of the autoimmune recurrence of T1DM in islet transplantation or endogenous islets.

229 ted with type 1 diabetes mellitus (allogenic islet transplantation), or the prevention of surgical di

230 ing SI_INS mRNA and SI_16h insulin predicted islet transplantation outcome in nonobese diabetic (NOD)

231 nors (H-2(d)) to assess alloimmunization and islet transplantation outcomes in Akita recipients.

232 trategies will be of assistance in improving islet transplantation outcomes.

233 re and may be a useful strategy in improving islet transplantation outcomes.

234 lted in significant delay of rejection after islet transplantation (P<0.01 vs. control).

235 al tools to follow patients after pancreatic islet transplantation (PIT).

236 The efficacy of pancreatic islet transplantation (PITx) is reduced due to islet dam

237 During intraportal pancreatic islet transplantation (PITx), early inflammatory reactio

238 cision-making before entering an intraportal islet transplantation protocol.

239 rategy to improve the efficiency of clinical islet transplantation protocols.

240 Islet transplantation provides a "cure" for type 1 diabe

241 Islet transplantation provides a promising approach for

242 Islet transplantation provides an approach to compensate

243 type 1 diabetic recipients after intraportal islet transplantation raises a question about the suitab

244 Fourteen islet transplantation recipients with long-term history

245 primary efficacy and the safety outcomes of islet transplantation reported to the NIDDK and JDRF fun

246 Islet transplantation represents a feasible therapeutic

247 ycemic variability compared with MDI whereas islet transplantation resolved hypoglycemia and further

248 intained for many years following successful islet transplantation, restoration of normal functional

249 However, in both groups, islet transplantation restored good glycemic control and

250 Our aim was to evaluate islet transplantation results at 1 year according to the

251 adverse events in Trials of Adult Pancreatic Islet Transplantation." RESULTS: There were no deaths or

252 cemia alone, coadministration of leptin with islet transplantation robustly improved control of gluco

253 duces an antibody-mediated rejection in this islet transplantation rodent model.

254 our own latest experience in the autologous islet transplantation setting.

255 ortal system may not be the optimal site for islet transplantation, several extrahepatic sites have b

256 tabolic outcomes of autologous and allogenic islet transplantation, shedding close light on our own l

257 ng during radiologic or surgical intraportal islet transplantation significantly impair primary graft

258 s a suitable polymer to create an artificial islet transplantation site under the skin and supports i

259 mation, which has important ramifications to islet transplantation studies.

260 ally delay graft destruction in future human islet transplantation studies.

261 Islet transplantation success depends on the number and

262 therapeutic treatments for diabetes such as islet transplantation techniques.

263 Muscle is a promising alternative site for islet transplantation that facilitates rapid restoration

264 is preclinical in vivo large animal model of islet transplantation, the effect of triple-drug immunos

265 ro and in vivo in syngeneic murine models of islet transplantation, the function of conformally coate

266 ld be beneficial to improve the outcomes for islet transplantation therapy.

267 aulic permeability and immune-protection for islet transplantation therapy.

268 In allogeneic model of islet transplantation, there was an initial islet loss a

269 reated 4 weeks before diabetes induction and islet transplantation through the transient placement of

270 s are lost in the early phase after clinical islet transplantation, through apoptosis, necrosis, or i

271 r immunosuppression limit the indication for islet transplantation to a small group of patients.

272 sirolimus+tacrolimus regimen 6 months before islet transplantation to exclude negative effects on kid

273 ous subcutaneous insulin infusion (CSII) and islet transplantation to reduce hypoglycemia and glycemi

274 insulin synthesis in islets is important for islet transplantation to succeed.

275 Here, we employ a sensitized murine model of islet transplantation to test strategies that promote lo

276 Islet transplantation to treat type 1 diabetes has been

277 immunity were performed antemortem after her islet transplantations to test in vitro for evidence of

278 Here we used an allogeneic murine islet transplantation tolerance model to examine the imp

279 bolic effects of diabetes were eliminated by islet transplantation (transplanted knockout (TKO)).

280 tion may lead to an alternative approach for islet transplantation treatment for diabetic patients.

281 active model for insulin supplementation and islet transplantation trials, and for studying developme

282 The long-term success of pancreatic islet transplantation (Tx) as a cure for type 1 diabetes

283 Immunosuppression (IS) in islet transplantation (Tx) is a double-edged sword: it p

284 Islet transplantation under the kidney capsule served as

285 ments for tolerance induction for xenogeneic islet transplantation using donor ECDI-SPs.

286 ation before and 6 months after intrahepatic islet transplantation using stepped hyperinsulinemic-hyp

287 Reversal of hyperglycemia by islet transplantation was most successful in recipients

288 Rodent allogeneic islet transplantation was performed from DA rats to Lewi

289 Islet transplantation was performed in hyperglycemic B-c

290 Using polymer scaffolds as a platform for islet transplantation, we investigated the hypothesis th

291 h T1D and end-stage renal failure undergoing islet transplantation were compared to 70 patients match

292 Islet transplantations were performed in partially pancr

293 ents reached normoglycemia after intraportal islet transplantation when they were treated with AAT co

294 unstable type 1 diabetes mellitus underwent islet transplantation with alemtuzumab induction and sir

295 Islet transplantation with alemtuzumab induction was wel

296 Isolated islet transplantation with infusions from two to three d

297 study, using a murine model of subcutaneous islet transplantation with matrigel basement membrane ma

298 development of more effective strategies for islet transplantation without immunosuppression.

299 le investigational agent for use in clinical islet transplantation without relying upon CD154 blockad

300 lopment of a novel strategy for pig-to-human islet transplantation without side effects of systemic i